Pharmaceutical preparations, for human use, for the prevention and treatment of myasthenia gravis.

Pharmaceutical preparations, for human use, for the prevention and treatment of paroxysmal nocturnal hemoglobinuria, myasthenia gravis, an inflammatory disorder, a wound, a burn, an autoimmune disorder, a pulmonary disorder, a cardiovascular disorder, a neurological disorder, a kidney-related disorder, a diabetes-related disorder, an ocular disorder, and a pregnancy-related disorder; pharmaceutical preparations, for human use, for the prevention and treatment of disorders of metabolism, the nervous system, the immune system, the cardio-vascular system, the respiratory system, the musculo-skeletal system, and the genitourinary system; pharmaceutical preparations for the treatment of fibrotic and inflammatory disorders; pharmaceutical preparations for use in dermatology, nephrology, hepatology, rheumatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; pharmaceutical preparations as anti-viral, anti-bacterial, or anti-fungal agents.

Syringes for injections; syringes for medical purposes; syringes for medical purposes sold empty which may be filled with pharmaceutical preparations, for human use, for the prevention and treatment of paroxysmal nocturnal hemoglobinuria, myasthenia gravis, an inflammatory indication, a wound, a burn, an autoimmune indication, a pulmonary indication, a cardiovascular indication, a neurological indication, a kidney-related indication, a diabetes-related indication, an ocular indication, and a pregnancy-related indication.